Wiesel Ory, Suharev Tatiyana, Awad Alaa, Abzah Lina, Laser-Azogui Adi, Mark Danieli Michal
Baruch Padeh-Tzafon Medical Center, Affiliated with the Azrieli Faculty of Medicine, Bar-Ilan University, Zefad 1528001, Israel.
EARLY O.M. Ltd., Netanya 4250363, Israel.
J Clin Med. 2024 Oct 16;13(20):6164. doi: 10.3390/jcm13206164.
Lung cancer is the leading cause of cancer-related mortality worldwide. Lung cancer screening and early detection resulted in a decrease in cancer-specific mortality; however, it introduced additional dilemmas and adherence barriers for patients and providers. Innovations such as biomolecular diagnosis and biosensor-based technology improve the detection and stratification of high-risk patients and might assist in overcoming adherence barriers, hence providing new horizons for better selection of screened populations. In the present manuscript, we discuss some of the dilemmas clinicians are currently facing during the diagnosis and treatment processes. We further highlight the potential benefits of a novel biosensor platform for lung cancer detection during the decision making process surrounding lung cancer.
肺癌是全球癌症相关死亡的主要原因。肺癌筛查和早期检测降低了癌症特异性死亡率；然而，它给患者和医护人员带来了额外的困境和依从性障碍。生物分子诊断和基于生物传感器的技术等创新改善了高危患者的检测和分层，并可能有助于克服依从性障碍，从而为更好地选择筛查人群提供新的前景。在本手稿中，我们讨论了临床医生在诊断和治疗过程中目前面临的一些困境。我们进一步强调了一种新型生物传感器平台在肺癌决策过程中用于肺癌检测的潜在益处。
